About Chorion-specific transcription factor GCMa
Chorion-specific transcription factor GCMa (GCM1) is a protein
from Homo sapiens identified by UniProt accession
Q9NP62, 436 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Chorion-specific transcription factor GCMa |
| UniProt accession | Q9NP62 |
| Gene | GCM1 |
| Organism | Homo sapiens |
| Length | 436 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (45)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.34
- folate deficiency · score 0.07
- fetal growth restriction · score 0.07
- HbA1c measurement · score 0.03
- age at first sexual intercourse measurement · score 0.02
- mean reticulocyte volume · score 0.02
- mean platelet volume · score 0.02
- lymphocyte count · score 0.02
- preeclampsia · score 0.02
- placenta disease · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NP62-F1 | alphafold | PREDICTED | 60.48 | — |
Amino-acid sequence (436 residues)
MEPDDFDSED KEILSWDIND VKLPQNVKKT DWFQEWPDSY AKHIYSSEDK NAQRHLSSWA MRNTNNHNSR ILKKSCLGVV VCGRDCLAEE GRKIYLRPAI CDKARQKQQR KRCPNCDGPL KLIPCRGHGG FPVTNFWRHD GRFIFFQSKG EHDHPKPETK LEAEARRAMK KVNTAPSSVS LSLKGSTETR SLPGETQSQG SLPLTWSFQE GVQLPGSYSG HLIANTPQQN SLNDCFSFSK SYGLGGITDL TDQTSTVDPM KLYEKRKLSS SRTYSSGDLL PPSASGVYSD HGDLQAWSKN AALGRNHLAD NCYSNYPFPL TSWPCSFSPS QNSSEPFYQQ LPLEPPAAKT GCPPLWPNPA GNLYEEKVHV DFNSYVQSPA YHSPQEDPFL FTYASHPHQQ YSLPSKSSKW DFEEEMTYLG LDHCNNDMLL NLCPLR
Explore Chorion-specific transcription factor GCMa with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets